Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Separate FDA Post-Market Drug Safety Office Outlined In Approps Bill Report

This article was originally published in The Pink Sheet Daily

Executive Summary

House subcommittee would provide FDA with $55 million more than the amount requested in President Obama's FY 2011 budget proposal.

You may also be interested in...



Separate FDA Safety Office Attached To House Report, Still Faces Steep Road

A proposal to establish an independent post-market drug surveillance office at FDA will face tough sledding if it comes up in the House Energy and Commerce Health Subcommittee.

Separate FDA Safety Office Attached To House Report, Still Faces Steep Road

A proposal to establish an independent post-market drug surveillance office at FDA will face tough sledding if it comes up in the House Energy and Commerce Health Subcommittee.

FDA Expects Sharp Drop In Fee-Paying Drug Applications This Year

In what could be viewed as an ominous sign of declining pharmaceutical R&D productivity, FDA is predicting a sharp drop-off in fee-paying drug and biologic applications in the current fiscal year

Related Content

Topics

UsernamePublicRestriction

Register

PS070845

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel